Verona Pharma Plc ADR (NASDAQ:VRNA) has a beta value of 0.45 and has seen 1.24 million shares traded in the last trading session. The company, currently valued at $3.18B, closed the last trade at $38.81 per share which meant it gained $0.95 on the day or 2.51% during that session. The VRNA stock price is -3.4% off its 52-week high price of $40.13 and 70.65% above the 52-week low of $11.39. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.2 million shares traded. The 3-month trading volume is 1.02 million shares.

The consensus among analysts is that Verona Pharma Plc ADR (VRNA) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 7 have rated it as a Hold, with 7 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.25.

Verona Pharma Plc ADR (NASDAQ:VRNA) trade information

Sporting 2.51% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the VRNA stock price touched $38.81 or saw a rise of 1.95%. Year-to-date, Verona Pharma Plc ADR shares have moved 95.22%, while the 5-day performance has seen it change 8.83%. Over the past 30 days, the shares of Verona Pharma Plc ADR (NASDAQ:VRNA) have changed 12.72%. Short interest in the company has seen 7.52 million shares shorted with days to cover at 8.04.

Wall Street analysts have a consensus price target for the stock at $36, which means that the shares’ value could drop -7.81% from current levels. The projected low price target is $26.0 while the price target rests at a high of $42.0. In that case, then, we find that the current price level is -8.22% off the targeted high while a plunge would see the stock lose 33.01% from current levels.

Verona Pharma Plc ADR (VRNA) estimates and forecasts

Figures show that Verona Pharma Plc ADR shares have underperformed across the wider relevant industry. The company’s shares have gained 222.34% over the past 6 months, with this year growth rate of -193.06%, compared to 18.00% for the industry. Revenue growth from the last financial year stood is estimated to be 0.00%.

7 analysts offering their estimates for the company have set an average revenue estimate of 12.89M for the current quarter. 5 have an estimated revenue figure of 20.45M for the next ending quarter.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 19.36% over the past 5 years.

VRNA Dividends

Verona Pharma Plc ADR is expected to release its next earnings report in December this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.

Verona Pharma Plc ADR (NASDAQ:VRNA)’s Major holders

Insiders own 4.13% of the company shares, while shares held by institutions stand at 89.40% with a share float percentage of 93.26%. Investors are also buoyed by the number of investors in a company, with Verona Pharma Plc ADR having a total of 192.0 institutions that hold shares in the company. The top two institutional holders are RA CAPITAL MANAGEMENT, L.P. with over 7.63 million shares worth more than $110.37 million. As of 2024-06-30, RA CAPITAL MANAGEMENT, L.P. held 9.4566% of shares outstanding.

The other major institutional holder is NEA MANAGEMENT COMPANY, LLC, with the holding of over 5.58 million shares as of 2024-06-30. The firm’s total holdings are worth over $80.76 million and represent 6.9193% of shares outstanding.

Also the top two Mutual Funds that are holding company’s shares are Federated Hermes Kaufmann Fund and Federated Hermes Kaufmann Small Cap Fund . As of Jul 31, 2024 , the former fund manager holds about 1.43% shares in the company for having 1.15 shares of worth $44.44 million while later fund manager owns 990.0 shares of worth $38.42 million as of Jul 31, 2024 , which makes it owner of about 1.24% of company’s outstanding stock.